ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 19 Dec 2022
Last Updated on 19 Dec 2022
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Dolutegravir 50 mg/lamivudine 300 mg tablet for treating Human Immunodeficiency Virus type 1 (HIV-1) infection

in view of acceptable proposal from the company.

Funding status

Dolutegravir 50 mg/lamivudine 300 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) from 1 February 2023.


Information on antiretroviral therapies previously recommended by the Drug Advisory Committee can be found in the Technology Guidance published on 1 September 2020 (Antiretroviral therapies for treating Human Immunodeficiency Virus type 1 (HIV-1) infection).



Dolutegravir with lamivudine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection (19 December 2022)